

05.10.02

L28C0 1615

Atty. Docket No.: 8654/2072

PATENT
TECH CENTER 1600/2900
MAY 15 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Krissansen, et al.
Serial No.: 10/014,887
Filed: December 11, 2001
Entitled: "Cancer Therapy"

Examiner:
Group Art Unit: 1615
Conf. No.: 2382

RECEIVED

CERTIFICATE OF EXPRESS MAILING

I hereby certify that the papers attached hereto are being deposited with the United States Postal Service using Express Mail to Addressee service, **Express Mail No. EV097555031US** on this date, May 9, 2002, postage prepaid under 37 C.F.R. Section 1.10 in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231.

David J. Dykeman
Name of Person Mailing Paper

Signature of Person Mailing Paper

Commissioner for Patents
Washington, D.C. 20231

TRANSMITTAL LETTER

Enclosed for filing in the above-identified patent application, please find the following documents:


1. Information Disclosure Statement;
2. Form PTO-1449 Citing 10 references;
3. Copies of 10 Cited References;
4. Return Post Card.

The Commissioner for Patents is hereby authorized to charge any additional fees or credit any overpayment in the total fees to Deposit Account No. 16-0085, Reference No. 58654/2002.
A duplicate of this transmittal letter is enclosed for this purpose.

Respectfully submitted,

Date: May 9, 2002

Name: David J. Dykeman
Registration No.: 46,678
Customer No.: 29933
Palmer & Dodge LLP
111 Huntington Avenue
Boston, MA 02199-7613
Tel: 617-239-0100



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Krissansen, et al.
Serial No.: 10/014,887
Filed: December 11, 2001
Entitled: "Cancer Therapy"

Atty. Docket No.: 8654/2072

PATE

Examiner:

Group Art Unit: 1615
Conf. No.: 2382


MAY 15 2002
TECH CENTER 1600/2904

CERTIFICATE OF EXPRESS MAILING

I hereby certify that the papers attached hereto are being deposited with the United States Postal Service using Express Mail to Addressee service, Express Mail No. EV097555031US on this date, May 9, 2002, postage prepaid under 37 C.F.R. Section 1.10 in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231.

David J. Dykeman

Name of Person Mailing Paper


Signature of Person Mailing Paper

Commissioner for Patents
Washington, D.C. 20231

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§ 1.56, 1.97 AND 1.98**

Dear Sir:

In accordance with the duty of disclosure under 37 CFR § 1.56, Applicant submits this Information Disclosure Statement pursuant to 37 CFR §§ 1.97 and 1.98 in the above-identified application for consideration by the Patent Office. A listing of the cited documents is also enclosed, as well as, for the Examiner's convenience, copies of the documents in the list.

Pursuant to CFR § 1.97(e)(1), each item contained in the Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application or International application. A copy of the PCT International Search Report for Application No. PCT/NZ00/00098 dated 31 October 2000 is included and cited in on the enclosed PTO-1449.


Because this statement is being filed before the mailing of the First Office Action on the merits, no fee is believed to be due. However, should the Office feel otherwise, the Commissioner is hereby authorized to charge any necessary fees to Deposit Account 16-0085, Reference No. 8654/2002.

Applicant does not intend to represent that any of the documents submitted herein are material prior art to this invention or that the list represents an exhaustive search of documents related to this invention.

Applicant respectfully requests that the documents submitted herein be considered and made of record in this application.

Date: May 9, 2002

Respectfully submitted,



Name: David J. Dykeman
Registration No.: 46,678
Customer No.: 29933
Palmer & Dodge LLP
111 Huntington Avenue
Boston, MA 02199-7613
Tel: 617-239-0100

RECEIVED

RECEIVED

MAY 15 2002

TECH CENTER 1600/2000



SPTO Form 1449 U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT				Attorney Docket No.		Serial No.	
				8654/2072		10/017,887	
				Applicant(s): Krissansen, et al.		Filing Date: December 11, 2001	
U.S. PATENT DOCUMENTS							
Examiner Initial		Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)
FOREIGN PATENT DOCUMENTS							
Examiner Initial		Document No.	Date	Country	Class	Subclass	Translation
							YES
	A.	EP0278176	August 17, 1998	Europe	C07D	311/86	
OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)							
	B.	PCT International Search Report for Application No. PCT/NZ00/00098 dated 31 October 2000					
	C.	Cao Z. et al. "Thalidomide increases both intra-tumoural tumour necrosis factor- α production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid" <u>British Journal of Cancer</u> (1999) volume 80(5/6), pages 716-723.					
	D.	Fujii H. et al. "Vaccination with B7-18 tumor and anti-adhesion therapy with RGD pseudo-peptide (FC-336) efficiently induce anti-metastatic effect" <u>Clinical & Experimental Metastasis</u> (1998) volume 16, pages 141-148.					
	E.	Pedley R.B. et al. "Ablation of colorectal xenografts with combined radioimmunotherapy and tumor blood flow-modifying agents" <u>Cancer Research</u> (1996) volume 56, pages 3293-3300.					
	F.	Zitvogel L. "Interleukin-12 and b7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumor" <u>Journal of Immunology</u> (1996) volume 26, pages 1335-13421.					
	G.	Lissoni P. et al. "Neuroimmunotherapy of advanced solid neoplasms with single evening subcutaneous injection of low-dose interleukin-2 and melatonin Preliminary results" <u>European Journal of Cancer</u> (1993) volume 29A(2), pages 185-189.					
	H.	Hornung R.L. et al. "Augmentation of natural killer activity, induction of IFN and development tumor activity during the successful treatment of established tumor murine renal cancer using flavoneacetic acid and IL-2" <u>The Journal of Immunology</u> (1998) volume 141(10), pages 3671-3679					
	I.	Nawrocki S. and Mackiewicz A. "Genetically modified tumour vaccines-where we are today" <u>Cancer Treatment Reviews</u> (1999) volume 25, pages 29-46.					
	J.	Thrash-Bingham C.A. and Tartof K.D. "aHIF: A natural antisense transcript overexpressed in human renal cancer during hypoxia" <u>The Journal of the National Cancer Institute</u> (1999) volume 91(2), pages 143-151					
EXAMINER				DATE CONSIDERED			
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.</small>							
<small>**Copies of references not provided at the time of this submission.</small>							